Literature DB >> 10554344

Late pleuropulmonary aspergillosis after the treatment of pneumothorax: report of three cases.

S Endo1, Y Sohara, F Murayama, T Yamaguchi, T Hasegawa, K Fuse.   

Abstract

A bullectomy for spontaneous pneumothorax is often combined with pleurodesis to prevent recurrence. A recurrent or progressive residual bullous lung beneath adhesive pleura neovascularized from the chest wall may be affected by aspergillosis. Of the 12 patients with pulmonary aspergillosis secondary to bullous lung disease treated surgically at our hospital since 1974, 3 underwent a bullectomy with pleurodesis for spontaneous pneumothorax. The presenting symptoms in all cases were hemosputum. Aspergillus lesions affected the patients in the right upper lobe, the left apical segment, and both apical segments at 16, 9, and 13 years, respectively, after a bullectomy. Angiograms demonstrated hypervascularization in the intercostal and internal thoracic arteries, as well as in the bronchial branches. Catheter embolization for airway bleeding was not effective in 1 patient. Four operations, including an emergency procedure for massive intrapulmonary bleeding, were performed. These included a right upper lobectomy followed by a left upper segmentectomy at second-look operation in 1 patient who required bilateral chest wall resections. All patients survived the operations. Intraoperative bleeding ranged between 700 and 3 500 ml (1 543 ml on average), and bleeding foci were mainly from the chest wall, with hypervascularization stemming from the ipsilateral chest wall. Postoperative complications included pleural space hemorrhaging and a bronchopleural fistula, both of which required additional chest wall resections. Patients with bullous lung disease late after a bullectomy with pleurodesis may thus be associated with complex pleuropulmonary aspergillosis, which requires surgical therapy concomitant with a chest wall resection.

Entities:  

Mesh:

Year:  1999        PMID: 10554344     DOI: 10.1007/s005950050658

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  9 in total

1.  Comparison of video-assisted thoracoscopic talcage for recurrent primary versus persistent secondary spontaneous pneumothorax.

Authors:  M Noppen; M Meysman; J d'Haese; I Monsieur; W Verhaeghe; M Schlesser; W Vincken
Journal:  Eur Respir J       Date:  1997-02       Impact factor: 16.671

2.  Characterization of amphotericin B aerosols for inhalation treatment of pulmonary aspergillosis.

Authors:  C Roth; J Gebhart; G Just-Nübling; B von Eisenhart-Rothe; I Beinhauer-Reeb
Journal:  Infection       Date:  1996 Sep-Oct       Impact factor: 3.553

3.  Use of nebulised liposomal amphotericin B in the treatment of Aspergillus fumigatus empyema.

Authors:  I F Purcell; P A Corris
Journal:  Thorax       Date:  1995-12       Impact factor: 9.139

4.  Treatment of hemoptysis by embolization of bronchial arteries.

Authors:  J Rémy; A Arnaud; H Fardou; R Giraud; C Voisin
Journal:  Radiology       Date:  1977-01       Impact factor: 11.105

Review 5.  Chronic necrotizing pulmonary aspergillosis: approach to management.

Authors:  J L Saraceno; D T Phelps; T J Ferro; R Futerfas; D B Schwartz
Journal:  Chest       Date:  1997-08       Impact factor: 9.410

6.  Pulmonary aspergilloma. Diagnostic and therapeutic considerations.

Authors:  R A Glimp; A S Bayer
Journal:  Arch Intern Med       Date:  1983-02

7.  Surgical treatment of pulmonary and pleuro-pulmonary Aspergillus disease.

Authors:  P Wex; E Utta; W Drozdz
Journal:  Thorac Cardiovasc Surg       Date:  1993-02       Impact factor: 1.827

8.  Intracavitary amphotereicin B in the treatment of symptomatic pulmonary aspergillomas.

Authors:  J L Hargis; R C Bone; J Stewart; N Rector; F C Hiller
Journal:  Am J Med       Date:  1980-03       Impact factor: 4.965

9.  Surgical treatment of pulmonary aspergilloma and Aspergillus empyema.

Authors:  T Shirakusa; H Ueda; T Saito; K Matsuba; J Kouno; N Hirota
Journal:  Ann Thorac Surg       Date:  1989-12       Impact factor: 4.330

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.